Dublin, Nov. 07, 2017 -- The "Nitric Oxide - Therapeutics, Markets and Companies" report from Jain PharmaBiotech has been added to Research and Markets' offering.
This report describes the latest concepts of the role of nitric oxide (NO) in health and disease as a basis for therapeutics and development of new drugs. Major segments of the market for nitric oxide-based drugs are described as well as the companies involved in developing them.
Important therapeutic areas for NO-based therapies are inflammatory disorders, cardiovascular diseases, erectile dysfunction, inflammation, pain and neuroprotection. The first therapeutic use of NO was by inhaltion for acute respiratory distress syndrome (ARDS). NO-donors, NO-mimics and NOS modulators are described and compared along with developmental status. NO-related mechanisms of action in existing drugs are identified.
Various pharmacological approaches are described along with their therapeutic relevance. Various approaches are compared using SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis. NO-based therapies are compared with conventional approaches and opportunities for combination with modern biotechnology approaches are described.
Share of drugs where NO is involved in the mechanism of action is analyzed in the worldwide pharmaceutical market for 2016 and is projected to 2021 and 2026 as new drugs with NO-based mechanisms are introduced into the market. Various strategies for developing such drugs are discussed.
Several companies have a product or products involving NO and free radicals. The report includes profiles of 35 companies involved in this area of which 9 have a significant interest in NO-based therapeutics. Other players are pharmaceutical and biotechnology companies as well as suppliers of products for NO research. Unfulfilled needs in the development of NO-based therapeutics are identified. Important 18 collaborations in this area are tabulated.
There are numerous publications relevant to NO. Selected 500 references are included in the bibliography. The text is supplemented with 26 tables and 29 figures.It is concluded that the future prospects for NO-based therapies are bright and fit in with biotechnology-based approaches to modern drug discovery and development. It is anticipated that some of these products will help in meeting the unfulfilled needs in human therapeutics.
Key Topics Covered:
Executive Summary
1. Introduction
2. Nitric Oxide Pathways
3. Role of NO in Physiology
4. Role of NO in Diseases
5. Pharmacology of Nitric Oxide
6. Therapeutic Applications
7. Evaluation of NO-Based Drugs
8. Markets for NO-based Therapies
9. Companies
10. References
For more information about this report visit https://www.researchandmarkets.com/research/mf57cj/nitric_oxide
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Healthcare Services


Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute
FTC Questions Apple News Over Alleged Bias Against Conservative Media
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 



